Pfizer Maraviroc Assay In HIV Is Model For Personalized Medicine, Firm Says
Executive Summary
Pfizer is putting forward its partnership with assay developer Monogram Biosciences to advance its CCR5 antagonist candidate maraviroc as a model for targeted drug development
You may also be interested in...
Pfizer Selzentry Will Launch At $29/Day; sNDA For Full Approval Slated For August
Pfizer's HIV therapy Selzentry (maraviroc) will be available in pharmacies by mid-September following FDA's Aug. 6 approval of the first-in-class CCR5 co-receptor antagonist
Pfizer Selzentry Will Launch At $29/Day; sNDA For Full Approval Slated For August
Pfizer's HIV therapy Selzentry (maraviroc) will be available in pharmacies by mid-September following FDA's Aug. 6 approval of the first-in-class CCR5 co-receptor antagonist
Pfizer’s Maraviroc Not Ready For Personalized Approach – Advisory Cmte.
FDA's Antiviral Drugs Advisory Committee is concerned about optimal dosing for Pfizer's HIV therapy maraviroc because the CCR5 co-receptor antagonist may have a narrow therapeutic window